Setting the state for tailored chemotherapy in the management of non-small cell lung cancer

Future Oncology

Volumn 4, Issue 1, 2008, Pages 51-59

  Simon, George R ^a   Begum, Mubeena ^a   Bepler, Gerold ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cisplatin; Docetaxel; ERCC1; Gemcitabine; Lung cancer; Nuclear excision repair; RRM1

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; MOLECULAR MARKER; NAVELBINE; PACLITAXEL; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG; DEOXYCYTIDINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; RRM1 PROTEIN, HUMAN; TAXOID; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TARGETING; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; HUMAN; IMAGING SYSTEM; INDIVIDUALIZATION; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MOLECULAR GENETICS; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SURVIVAL TIME; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM; PREDICTION AND FORECASTING; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 39549094264     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.1.51     Document Type: Review

References (14)